hotspot -WSS

hotspot

author：entertainment 2025-09-30 00:39:13 - browse：7424

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Medical device lobby: We're tired of waiting on Medicare coverage

knowledge

WSS

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Oral obesity drug from Viking Therapeutics hits key early target

Hundreds died while taking an arthritis drug, but nobody alerted patients

Flu vaccine offering decent levels of protection this winter, new data show

Kenai launches with $82 million for Parkinson’s stem cell therapy

UnitedHealth, in a surprise, takes aim at Steward’s physician group

hotspot

hotspot

knowledge

Activists slam private health insurers over coverage restrictions

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

After affirmative action ruling, medical educators look to 'holistic review'

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Heart attack and stroke risk calculators need revising

Covid isolation guidance eased by the CDC

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Young boy dies in trial for Pfizer Duchenne gene therapy

The high cost of giving birth even with insurance

Harvard scientists, with Google, unveil the most detailed brain map ever

leisure time

Researchers test human milk's ability to repair gut microbiome

In search for therapies for solid tumors, companies turn to claudin

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

U.K. decision on ALS drug has neurologists, advocates up in arms

Insurer loopholes limit power of law against surprise medical bills

People with mental disorders often marry others with same

focus

knowledge

focus

entertainment